Table 2.
Different assay performance of UCP-LFAs in high-dose and low-dose MTB infected rhesus macaques.
| (a). AUCs of high-dose MTB infected RMs (n = 24) | ||||||
| wk3 | wk6 | wk9 | wk12 | |||
| SAA1 | 0.903 | 0.951 | 0.894 | 0.889 | ||
| IP-10 | 0.858 | 0.984 | 1.000 | 0.956 | ||
| IL-6 | 0.854 | 0.938 | 0.955 | 0.905 | ||
| 3BM | 0.948 | 0.997 | 0.996 | 0.968 | ||
| (b). AUCs of low-dose MTB infected RMs (n = 12) | ||||||
| wk2 | wk4 | wk6 | wk8 | wk10 | wk12 | |
| SAA1 | 0.531 | 0.868 | 0.747 | 0.763 | 0.750 | 0.774 |
| IP-10 | 0.646 | 0.944 | 0.944 | 0.883 | 0.870 | 0.952 |
| IL-6 | 0.597 | 0.795 | 0.799 | 0.783 | 0.655 | 0.571 |
| 3BM | 0.583 | 0.8958 | 0.875 | 0.858 | 0.964 | 0.821 |
SAA1, IP-10 and IL-6 levels were measured by UCP-LFA before and at several time points after (a) high-dose (500 CFU, n = 24) or (b) low-dose (15 CFU, n = 12) MTB Erdman infection. The ability to distinguish pre from postinfection states was evaluated per marker and for the 3BM (3 biomarkers) signature by ROC curve analysis over time, and the corresponding Area Under the Curve (AUC) was determined (ROC-AUC). Values above the cutoff per biomarker (described in Table 1b) were considered positive. 3BM signature was generated using the sum of all positive tests results from the individual markers. wk, week; RM, rhesus macaque; BM, biomarker.